仁度生物(688193) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥43,963,532.37, representing an increase of 18.60% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥340,385.76, a decrease of 81.59% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was -¥3,026,637.66, a decrease of 2,415.56% compared to the same period last year[2]. - Total operating revenue for the first three quarters of 2024 reached ¥130,643,714.19, an increase from ¥117,098,308.04 in the same period of 2023, representing a growth of approximately 11.5%[16]. - The net profit for the first three quarters of 2024 was ¥4,671,196.93, a significant recovery from a net loss of ¥8,343,228.52 in the same period of 2023[18]. - The total comprehensive income for the first three quarters of 2024 was ¥4,256,521.81, a recovery from a loss of ¥7,140,501.82 in the same period of 2023[19]. Research and Development - R&D expenses totaled ¥9,314,746.89 in Q3 2024, accounting for 21.19% of revenue, a decrease of 8.76 percentage points year-on-year[4]. - Research and development expenses remained stable at ¥29,996,309.80, slightly up from ¥29,704,497.58, reflecting continued investment in innovation[18]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,005,295,397.07, a decrease of 4.69% from the end of the previous year[4]. - The total current assets were RMB 857,082,886.04, down from RMB 899,141,593.82 in the previous period[13]. - The company's cash and cash equivalents were RMB 235,075,162.53, compared to RMB 609,567,016.44 at the end of 2023, indicating a significant decrease[13]. - The total liabilities stood at RMB 78,015,501.41, down from RMB 91,974,054.59[15]. - The total equity attributable to shareholders was RMB 927,279,895.66, a decrease from RMB 962,741,641.49[15]. - The non-current assets totaled RMB 148,212,511.03, down from RMB 155,574,102.26[14]. Cash Flow - The company reported a net cash flow from operating activities of ¥16,575,482.78 for the year-to-date period, with stable inventory levels compared to last year[7]. - The net cash flow from operating activities for Q3 2024 was ¥16,575,482.78, a significant improvement from a net outflow of ¥12,018,719.88 in the same period last year[21]. - Total cash inflow from investment activities was ¥597,723,171.14, compared to ¥589,138,811.22 in Q3 2023[21]. - The net cash flow from investment activities showed a substantial decline, with a net outflow of ¥345,335,011.47 compared to a net inflow of ¥398,397,394.59 in the previous year[21]. - Cash and cash equivalents at the end of Q3 2024 amounted to ¥234,774,162.53, down from ¥681,526,214.46 at the end of Q3 2023[22]. - The total cash outflow from financing activities was ¥45,458,925.34, compared to ¥7,568,520.97 in the same quarter last year[21]. Shareholder Information - The equity attributable to shareholders at the end of Q3 2024 was ¥927,279,895.66, down 3.68% from the previous year[4]. - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[12]. Other Financial Metrics - The basic earnings per share for Q3 2024 was ¥0.0085, a decrease of 78.75% compared to the same period last year[4]. - Basic and diluted earnings per share for the first three quarters of 2024 were both ¥0.12, compared to a loss of ¥0.21 per share in the same period of 2023[19]. - Cash received from sales and services was ¥143,717,484.22, down from ¥155,386,544.15 in the previous year, indicating a decrease of approximately 7.5%[20]. - The cash flow impact from exchange rate changes was a negative ¥273,399.88, contrasting with a positive impact of ¥4,082,877.23 in the previous year[22]. - The company received tax refunds totaling ¥3,211.13, an increase from ¥2,078.36 in the previous year[21]. - Cash paid to employees decreased to ¥64,207,125.96 from ¥71,384,164.01 year-over-year[21]. - The company reported cash outflows related to operating activities totaling ¥136,471,385.48, down from ¥175,211,819.26 in Q3 2023[21]. Strategic Outlook - The company plans to continue its growth strategy, focusing on stable revenue growth and investment in financial products to enhance non-recurring gains[7].